Cargando…
Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease
BACKGROUND: Myxomatous mitral valve disease (MMVD), a naturally occurring heart disease, affects 10% to 15% of the canine population. Canine MMVD shares many similarities with human MMVD. Untargeted metabolomics was performed to identify changes in metabolic pathways and biomarkers with potential cl...
Autores principales: | Li, Qinghong, Larouche‐Lebel, Éva, Loughran, Kerry A., Huh, Terry P., Suchodolski, Jan S., Oyama, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200728/ https://www.ncbi.nlm.nih.gov/pubmed/33890477 http://dx.doi.org/10.1161/JAHA.120.018923 |
Ejemplares similares
-
Gut Dysbiosis and Its Associations with Gut Microbiota-Derived Metabolites in Dogs with Myxomatous Mitral Valve Disease
por: Li, Qinghong, et al.
Publicado: (2021) -
Echocardiographic indices and severity of mitral regurgitation in dogs with preclinical degenerative mitral valve disease
por: Larouche‐Lebel, Éva, et al.
Publicado: (2019) -
Serum untargeted metabolomic changes in response to diet intervention in dogs with preclinical myxomatous mitral valve disease
por: Li, Qinghong, et al.
Publicado: (2020) -
Effect of angiotensin receptor blockers and angiotensin converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in dogs with heart disease
por: Larouche‐Lebel, Éva, et al.
Publicado: (2020) -
Plasmatic Dimethylarginines in Dogs With Myxomatous Mitral Valve Disease
por: Valente, Carlotta, et al.
Publicado: (2021)